An integrated systems approach aimed at identifying cancer genes that disfavor T-cell immunity revealed that up-regulation of anti-apoptotic proteins, particularly BCL-2 and BCL-XL, which have been widely implicated in drug resistance to chemotherapy and targeted therapies, also promotes tumor resistance to immunotherapy independent of PD-L1 expression levels [102]. This evidence concerns the gene BCL2L1 and neoplasm.